Skip to content Skip to footer

Oliver Ahnfeld is a co-founder of PROVIREX. He has been one of the CEOs of the company since its inception in 2019, and has focused on its entrepreneurial transformation into a biotech company. He has been part of the team for more than 8 years and is responsible for the financial/contractual aspects and the strategic direction of PROVIREX. He studied industrial engineering in Hamburg and has several years of experience in preparing business and financial plans as well as accompanying private placements.

Genome Editing Therapies GmbH

Luruper Hauptstraße 1
22547 Hamburg


Copyright © PROVIREX Genome Editing Therapies GmbH 2023